KLX Energy Services Holdings, Inc. filed a Form 8-K/A on November 4, 2026, amending its October 29, 2026 Current Report to correct the stated basis for the Board appointments of Franklin S. Edmonds, Jr. and E. Dirk Hallen as independent directors.
Valuence Merger Corp. I filed a Form 8-K on November 4, 2026, disclosing that its board of directors approved a one-month extension of the deadline to complete an initial business combination, from November 3, 2026 to December 3, 2026, and deposited $13,897.14 into the …
Nordicus Partners Corporation filed a Form 8-K on November 4, 2026, disclosing the October 29, 2026 closing of a private placement in which 40,000 restricted shares of common stock were issued to two private investors at $2.00 per share, raising $80,000 in proceeds.
New America Acquisition I Corp. filed a Form 8-K on November 4, 2026, disclosing that its Board of Directors has scheduled the company's first Annual Meeting of Stockholders for December 22, 2026, to be held virtually, with a record date of November 13, 2026.
Karat Packaging Inc. filed a Form 8-K with the SEC on November 4, 2026, disclosing that its Board of Directors declared a regular quarterly cash dividend of $0.47 per share on the company's common stock.
Annovis Bio, Inc. filed a Form 8-K on November 4, 2026, disclosing that stockholders approved an amendment to the company's Amended and Restated Certificate of Incorporation at a Special Meeting held telephonically on November 3, 2026, doubling authorized common shares from 70,000,000 to 140,000,000.
Annovis Bio, Inc. filed a Form 8-K on November 4, 2026, disclosing a preliminary, unaudited estimate that its cash and cash equivalents were approximately $2.8 million as of September 30, 2026.
SmartStop Self Storage REIT, Inc. filed a Current Report on Form 8-K on November 4, 2026, disclosing that it issued a press release on the same date announcing its financial results for the three and nine months ended September 30, 2026.
Emergent BioSolutions Inc. filed a Form 8-K on November 4, 2026, disclosing a contract modification exercising an option period to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War for a value of up to $22.3 million.
Pacific Biosciences of California, Inc. filed an 8-K on November 4, 2026, disclosing a Chief Financial Officer transition effective November 3, 2026, the appointment of an interim CFO, and the appointment of a new Chief Accounting Officer, alongside the announcement of third-quarter 2026 financial …